Publications by authors named "Ellen Poot"
Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has experienced no changes in treatment for nearly two decades and has a 5-year survival rate of only 5.4%. Alongside challenges in delivering chemotherapeutic agents across the blood brain barrier (BBB) to the tumour, the immune microenvironment is also heavily influenced by tumour signalling.
View Article and Find Full Text PDFArticle Synopsis
- Pharmacogenomics (PGx) can personalize treatment for patients and reduce healthcare costs, but its implementation in practice is still limited.
- A pilot study with patients, pharmacists, and physicians highlighted barriers like a lack of education on PGx, unclear responsibilities among practitioners, and reliance on computer systems that have practical issues.
- Despite these challenges, stakeholders generally have a positive view of PGx, especially when supported by available guidelines and clinical decision support (CDS) tools.